Vaccinex (VCNX) stock forecast for 2022
Last update: September 19, 2022 (07:45)Sector: Healthcare
The share price of Vaccinex, Inc. (VCNX) now
What analysts predict:: $7
52-week high/low: $2.37 / $0.7
50/200 Day Moving Average: $1.002 / $1.204
This figure corresponds to the average price over the previous 50/200 days. For Vaccinex stocks, the 50-day moving average is the resistance level today.
For Vaccinex stocks, the 200-day moving average is the resistance level today.
Are you interested in Vaccinex stocks and want to buy them, or are they already in your portfolio? If yes, then on this page you will find useful information about the dynamics of the Vaccinex stock price in 2022. How much will one Vaccinex share be worth in 2022?
Is it worth taking profit / loss on Vaccinex stock now or waiting? What are analysts' forecasts for Vaccinex stock?
We forecast Vaccinex stock performance using neural networks based on historical data on Vaccinex stocks. Also, when forecasting, technical analysis tools are used, world geopolitical and news factors are taken into account.
The Vaccinex stock prediction results are shown below and presented as a graph, table and text information.
Vaccinex stock forecasts are adjusted once a day based on the closing price of the previous trading day.
The minimum target price for Vaccinex analysts is $7.
Today 200 Day Moving Average is the resistance level (1.204 $).
50 Day Moving Average is the resistance level (1.002 $).
Historical and forecast chart of Vaccinex stock
The chart below shows the historical price of Vaccinex stock and a prediction chart for the next year. For convenience, prices are divided by color. Forecast prices include: Optimistic Forecast, Pessimistic Forecast, and Weighted Average Best Forecast. Detailed values for the Vaccinex stock price can be found in the table below.
Vaccinex (VCNX) Forecast for 2022
Vaccinex information and performance
Vaccinex Inc is a clinical-stage biotechnology company. It is engaged in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. The company’s product pipeline includes pepinemab (VX15), which targets Huntington’s Disease (HD) and non-small cell lung cancer (NSCLC) and also neurodegenerative disorders; VX5 Autoimmune for the treatment of MS and potentially for other autoimmune disorder; and others.
1895 MOUNT HOPE AVE, ROCHESTER, NY, US
Market Capitalization: 34 016 100 $
Market capitalization is the total market value of all issued shares of a company. It is calculated by the formula multiplying the number of shares in the company outstanding by the market price of one share.
EBITDA: -20 403 000 $
EBITDA is earnings before interest, income tax and depreciation of assets.
PE Ratio: None
P/E ratio (price to earnings) - shows the ratio between the price of a share and the company's profit
PEG Ratio: None
Price/earnings to growth
Dividend Per Share is a financial indicator equal to the ratio of the company's net profit available for distribution to the annual average of ordinary shares.
Dividend yield is a ratio that shows how much a company pays in dividends each year at the stock price.
EPS shows how much of the net profit is accounted for by the common share.
Quarterly Earnings Growth YOY: N/A
Quarterly Revenue Growth YOY: -0.92
Trailing PE: -
Trailing P/E depends on what has already been done. It uses the current share price and divides it by the total earnings per share for the last 12 months.
Forward PE: -
Forward P/E uses projections of future earnings instead of final numbers.
EV To Revenue: 457.7
Enterprise Value (EV) /Revenue
EV To EBITDA: -1.173
The EV / EBITDA ratio shows the ratio of the cost (EV) to its profit before tax, interest and amortization (EBITDA).
Shares Outstanding: 42664100
Number of issued ordinary shares
Shares Float: N/A
Number of freely tradable shares
Shares Short Prior Month: N/A
Shares Short Prior Month - the number of shares in short positions in the last month.
Short Ratio: N/A
Percent Insiders: N/A
Percent Institutions: N/A
Vaccinex price target for 2021 by month
Target values for the price of one Vaccinex share for Oct 2022.
Pessimistic target level: 0.75
Optimistic target level: 0.84
Target values for the price of one Vaccinex share for Nov 2022.
Pessimistic target level: 0.84
Optimistic target level: 0.99
Target values for the price of one Vaccinex share for Dec 2022.
Pessimistic target level: 0.88
Optimistic target level: 1.01
Related stocks from Healthcare sector
All forecast data on the site are provided for informational purposes of using neural forecasting tools in the financial market and are not a call to action and, moreover, are not trading signals. When using the forecast data, the investor assumes all financial risks. The pandaforecast.com portal is not responsible for the loss of your money in the stock market as a result of using the information contained on the site.